These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30106164)

  • 1. Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.
    Weissenrieder JS; Reilly JE; Neighbors JD; Hohl RJ
    Prostate; 2019 Jan; 79(1):21-30. PubMed ID: 30106164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-6 induces VEGF secretion from prostate cancer cells in a manner independent of androgen receptor activation.
    Ishii K; Sasaki T; Iguchi K; Kajiwara S; Kato M; Kanda H; Hirokawa Y; Arima K; Mizokami A; Sugimura Y
    Prostate; 2018 Aug; 78(11):849-856. PubMed ID: 29707793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer.
    Chen WY; Zeng T; Wen YC; Yeh HL; Jiang KC; Chen WH; Zhang Q; Huang J; Liu YN
    Cancer Lett; 2019 Jan; 440-441():35-46. PubMed ID: 30312731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of androgen receptor by 3,3'-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells.
    Bhuiyan MM; Li Y; Banerjee S; Ahmed F; Wang Z; Ali S; Sarkar FH
    Cancer Res; 2006 Oct; 66(20):10064-72. PubMed ID: 17047070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
    Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The β
    Braadland PR; Ramberg H; Grytli HH; Urbanucci A; Nielsen HK; Guldvik IJ; Engedal A; Ketola K; Wang W; Svindland A; Mills IG; Bjartell A; Taskén KA
    Mol Cancer Res; 2019 Nov; 17(11):2154-2168. PubMed ID: 31395667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of androgen receptors by NaAsO
    Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
    Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
    Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
    Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. hASH1 nuclear localization persists in neuroendocrine transdifferentiated prostate cancer cells, even upon reintroduction of androgen.
    Fraser JA; Sutton JE; Tazayoni S; Bruce I; Poole AV
    Sci Rep; 2019 Dec; 9(1):19076. PubMed ID: 31836808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells.
    Ciarlo M; Benelli R; Barbieri O; Minghelli S; Barboro P; Balbi C; Ferrari N
    Int J Cancer; 2012 Aug; 131(3):582-90. PubMed ID: 22015967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of prostate cancer cell lines for androgen receptor-mediated reporter gene assays.
    Kim HJ; Park YI; Dong MS
    Toxicol In Vitro; 2006 Oct; 20(7):1159-67. PubMed ID: 16621434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
    Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
    Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells.
    Wright ME; Tsai MJ; Aebersold R
    Mol Endocrinol; 2003 Sep; 17(9):1726-37. PubMed ID: 12775765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation.
    Marchiani S; Tamburrino L; Nesi G; Paglierani M; Gelmini S; Orlando C; Maggi M; Forti G; Baldi E
    Int J Androl; 2010 Dec; 33(6):784-93. PubMed ID: 20088946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation and caspase activation.
    Agabiti SS; Li J; Wiemer AJ
    Cell Death Dis; 2017 Mar; 8(3):e2678. PubMed ID: 28300835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Infiltrating mast cells promote neuroendocrine differentiation and increase docetaxel resistance of prostate cancer cells by up-regulating p21].
    Ou YH; Jiang YD; Li Q; Zhuang YJ; Dang Q; Tan WL
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jun; 38(6):723-730. PubMed ID: 29997096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
    Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.
    Wiemer AJ; Tong H; Swanson KM; Hohl RJ
    Biochem Biophys Res Commun; 2007 Feb; 353(4):921-5. PubMed ID: 17208200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
    Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
    Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.